Bailey Griffin, DPM
Foot & Ankle Surgery · Humble, TXNPI 1003164146
Payments from drug & device makers
What this record shows
This record is dominated by other: $38,400 of the $44,052 with a category attached, or 87.2%. Triad Life Sciences Inc. accounts for 87.2% of it on its own, with 53 other manufacturers making up the rest. Reporting peaked in 2022 at $39,616 and has fallen 97.7% since, to $910 in 2025. Among foot & ankle surgery clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 191 payments — averaging $230.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Triad Life Sciences Inc.$38K
- Stryker$1K
- Smith+Nephew$554
- Sanara Medtech Inc.$471
- Zimmer Biomet$209
- Heartflow, Inc.$205
- plus $3K from 48 others
What the payments were for
- Food & beverage$5,65213%
- Other$38,40087%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NOVAFIX$38,400
- CellerateRx$408
- PuraPly$182
- Barostim Neo System$171
- CERAMENTBONE VOID FILLER$154
- CANNULATED SCREWS$133
- FFRct$115
- ENSITE$112
How this compares
$44,052 in reported general payments places this provider in the 90th percentile of 684 foot & ankle surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gentamicin Sulfate | 279 | $10,451 |
| Naftifine Hcl | 12 | $3,529 |
| Gabapentin | 333 | $2,776 |
| Pregabalin | 25 | $682 |
| Doxycycline Monohydrate | 51 | $573 |
| Econazole Nitrate | 17 | $563 |
| Methylprednisolone | 77 | $517 |
| Terbinafine Hcl | 45 | $494 |
| Ketoconazole | 27 | $463 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 13 | $434 |
| Clindamycin Hcl | 44 | $431 |
| Mupirocin | 21 | $269 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 33 | $252 |
| Ciprofloxacin Hcl | 34 | $216 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 62 | $195 |
Paid to pharmacies, not to this prescriber.
Other foot & ankle surgery in Humble
- William McGarveyKaty$3.5M
- Eugene CurryDallas$3.1M
- Graham HamiltonEdinburg$2.1M
- Mark DaltonAustin$1.9M
- Kevin VarnerHouston$1.1M
- Paul KimDallas$928K
- Sherman NaglerHouston$602K
- John EarlyDallas$553K
- Michael DowneySouthlake$475K
- Abdul NurudeenHouston$404K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.